Driver gene status and first line treatment of advanced lung adenocarcinoma:A single centric real-world study
10.3969/j.issn.1006-5725.2019.04.008
- VernacularTitle:晚期肺腺癌驱动基因分布及其一线治疗现状——单中心真实世界研究
- Author:
Ning SU
1
;
Xianlan ZHANG
;
Huiyi HUANG
;
Yun JIN
;
Yalin XIE
;
Wei ZHOU
;
Jingrong HE
;
Wen-Chang CEN
Author Information
1. 广州市胸科医院肿瘤科
- Keywords:
lung neoplasms;
adenocarcinoma;
driver gene
- From:
The Journal of Practical Medicine
2019;35(4):537-540
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze driver genes status and its clinical characteristics of advanced lung adenocarcinoma, then evaluate the status of first-line treatment in a single centric real-world. Methods EGFR, ALK, ROS-1 gene in 204 advanced lung adenocarcinoma tissue were tested by ARMS-PCR method. And the relationship between driver genes status and clinical characteristics was analyzed as the first line treatment in real clinical practice. Results The positive rate of driver genes status in 204 advanced lung adenocarcinoma was 53.9％ (110/204) , including EGFR mutation 46.1％ (94/204) , ALK positive 6.4％ (13/204) and ROS1 positive 1.5％ (3/204). The driving genes status was significantly correlated with gender, smoking history, tumor staging and serosal invasion (P < 0.05). There were significantly differences among the proportion of first-line standard treatment in different subgroup (P = 0.000) , the first-line standard treatment rate of EGFR mutation, ALK/ROS1 positive and drive gene negative were 77.7％, 37.5％, and 46.8％ respectively. And the ratio of using 1 st generation EGFR-TKIs in all patients is 70.6％ (60/85). Conclusion More than half of advanced lung adenocarcinoma have driver genes changes, and EGFR-TKI first-line treatment has higher acceptability in real-word.
